Avidity Partners Management LP Iovance Biotherapeutics, Inc. Transaction History

Avidity Partners Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$9.53 - $13.11 $89,582 - $123,234	-9,400 Reduced 0.68%	1,382,900 $13.2 Million
Q2 2022 Aug 15, 2022	SELL	$6.38 - $18.33 $29.7 Million - $85.3 Million	-4,650,919 Reduced 76.96%	1,392,300 $15.4 Million
Q1 2022 May 16, 2022	BUY	$12.38 - $19.1 $28 Million - $43.2 Million	2,263,219 Added 59.87%	6,043,219 $101 Million
Q4 2021 Feb 14, 2022	BUY	$16.55 - $27.63 $38.4 Million - $64 Million	2,317,800 Added 158.51%	3,780,000 $72.2 Million
Q3 2021 Nov 15, 2021	BUY	$20.35 - $26.63 $29.8 Million - $38.9 Million	1,462,200 New	1,462,200 $36.1 Million
Q4 2020 Feb 16, 2021	SELL	$28.04 - $50.26 $22.4 Million - $40.2 Million	-799,000 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$27.75 - $36.3 $1.68 Million - $2.19 Million	60,453 Added 8.19%	799,000 $26.3 Million
Q2 2020 Aug 14, 2020	BUY	$27.21 - $41.0 $20.1 Million - $30.3 Million	738,547 New	738,547 $20.3 Million

316

239M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $933M
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

Stay updated on Avidity Partners Management LP with notifications on news.